ALK-positive ALCL, which is resistant to crizotinib, could be treated with a blockade of platelet-derived growth factor receptor-β (PDGFRB), which has been shown to encourage lymphoma development and tumor propagation in mouse models of ALCL with NPM-ALK fusions. This evidence concerns the gene PDGFRB and anaplastic large cell lymphoma.